What question did this study set out to answer?

This research aims to explore how GLP-2 impacts osteoblasts to combat postmenopausal osteoporosis through molecular pathways.

January 25, 2026

GLP-2 alleviates postmenopausal osteoporosis by acting on osteoblasts through the PI3K/AKT/FOXO1 signalling pathway to downregulate FGF23 expression.

Key Points

This research aims to explore how GLP-2 impacts osteoblasts to combat postmenopausal osteoporosis through molecular pathways.
Activated PI3K/AKT/FOXO1 pathway in osteoblasts using GLP-2 treatment
Monitored FGF23 expression levels in response to GLP-2
Analyzed the effect on osteoporosis in a postmenopausal model
GLP-2 effectively activates the PI3K/AKT/FOXO1 pathway in osteoblasts
Significant downregulation of FGF23 expression observed
Improved indicators of osteoporosis noted in treated models

Abstract

GLP-2 ameliorates postmenopausal osteoporosis by activating the PI3K/AKT/FOXO1 pathway in osteoblasts, leading to FGF23 downregulation. These findings provide novel molecular insights and potential therapeutic targets for the use of GLP-2 in osteoporosis management.

Bookmark

Cite This Study

Wu et al. (Thu,) studied this question.

synapsesocial.com/papers/6975b32bfeba4585c2d6ea62 https://doi.org/https://doi.org/10.1186/s13018-026-06661-2

Bookmark